Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

The American Journal of Medicine

Volumn 91, Issue 2, 1991, Pages 162-168

  Cherin, Patrick ^a   Herson, Serge ^a   Wechsler, Bertrand ^a   Piette, Jean Charles ^a   Bletry, Olivier ^a   Coutellier, Anne ^a   Ziza, Jean Marc ^a   Godeau, Pierre ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; METHOTREXATE;

ADULT; AGED; ARTICLE; CASE REPORT; DERMATOMYOSITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; POLYMYOSITIS; PRIORITY JOURNAL;

ADULT; CHRONIC DISEASE; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLOBULINS; HUMAN; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGE; MYOSITIS; REMISSION INDUCTION;

EID: 0026074908     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(91)90009-M     Document Type: Article

References (44)

1. Immunological aspects of polymyositis
2. Immunohistochemical characterization of the mononuclear cells infiltrating muscle of patients with inflammatory and noninflammatory myopathies
3. Steroid therapy in patients with polymyositis and dermatomyositis
4. Methotrexate therapy in polymyositis
5. Treatment of polymyositis with immunosuppressive drugs
6. Cyclosporin in juvenile dermatomyositis
7. Patients with polymyositis and dermatomyositis who undergo plasmapheresis therapy
8. Polymyositis: remarkable response to total body irradiation [letter]
9. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
10. High dose intravenous gammaglobulin for Kawasaki disease
11. Reversal of chronic polymyositis following intravenous immune serum globulin therapy
12. Polymyositis and dermatomyositis
13. Polymyositis and dermatomyositis
14. Intravenous immunoglobulins as therapeutic agents
15. Lymphotoxin formation by lymphocytes and muscle in polymyositis
16. Abnormalities of lymphocyte subsets in polymyositis
17. Macrophage migration inhibition studies of lympho-cytes taken from guinea-pigs suffering from experimental polymyositis
18. Microvascular deposition of complement membrane attack complex in dermatomyositis
19. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy
20. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis
21. Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies
22. Dermatomyositis (systemic angiopathy) of childhood
23. Dermatomyositis of childhood: ultrastructural alterations of muscle and intramuscular vessels
24. Dermatomyositis, polymyositis, and coxsackie-B-virus infection
25. Polymyositis and molecular mimicry, a mechanism of autoimmunity
26. Polymyositis associated with AIDS retrovirus
27. Serologic evidence for acute toxoplasmosis in polymyositis-dermatomyositis
28. Echovirus disease in hypogammaglobulinemia patients
29. HTLV-I polymyositis in a patient also infected with the human immunodeficiency virus
30. D-penicillamine-induced polymyositis in rheumatoid arthritis
31. Cimetidine and polymyositis
32. Immunologic thrombocytopenic purpura in HIV-seropositive narcotic addicts
33. Successful response to intravenous immunoglobulin in auto-immune haemolytic anaemia
34. High dose intravenous gammaglobulin for myasthenia gravis
35. Gammaglobulin therapy in 6 newly diagnosed diabetic children
36. Globulin treatment for lupus nephritis (LN), membranous nephropathy (MN), and membranoproliferative glomerulonephritis (MPGN), long term follow up study
37. Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis
38. Intravenous immunoglobulin in polymyositis and dermatomyositis
39. Intravenous immunoglobulin in polymyositis and dermatomyositis
40. Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA
41. Anti-idiotypic immunity and autoimmunity
42. Anti-idiotypic antibodies against anti-phospholipid autoantibodies which suppress lupus-like anticoagulant activity
43. Clinical uses of intravenous immunoglobulins